Supplementary Table1. Previous regimens.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | First-line therapy | | Second-line therapy | | Third-line therapy | |
| Treatment regimen | Erlotinib | S-1 | Erlotinib | S-1 | Erlotinib | S-1 |
|  | (n = 19) | (n = 18) | (n = 19) | (n = 18) | (n = 3) | (n = 5) |
| Platinum-based doublets | 19 | 17 | 2 | 6 | 0 | 1 |
| Pemetrexed | 11 | 11 | 1 | 4 | 0 | 0 |
| Paclitaxel | 5 | 4 | 0 | 2 | 0 | 0 |
| Gemcitabine | 2 | 0 | 0 | 0 | 0 | 0 |
| Irinotecan | 0 | 1 | 0 | 0 | 0 | 0 |
| Docetaxel | 1 | 1 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 |
| Single-agent |  |  |  |  |  |  |
| Docetaxel | 0 | 1 | 13 | 11 | 1 | 2 |
| Amurubicin | 0 | 0 | 1 | 1 | 1 | 0 |
| Pemetrexed | 0 | 0 | 3 | 0 | 0 | 2 |
| Vinorelbine | 0 | 0 | 0 | 0 | 1 | 0 |